

ondine



For Immediate Release

**Ondine Announces Clinical Advisory Board Member is Recipient of the 2007 IADR
Periodontal Disease Research Award**

Vancouver, Canada – May 7, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) announces that Dr. Richard Darveau, a member of its Clinical Advisory Board, is the recipient of the 2007 Basic Research in Periodontal Disease Award from the International Association for Dental Research (IADR). This recognition was awarded for his work exploring the significance of the constant low level of inflammation, present in the healthy periodontium, induced by commensal micro-organisms. Dr. Darveau is also engaged in researching the effect of Periowave™ on neutralizing the virulence factors produced by intra-oral bacteria.

“Dr. Darveau along with the other esteemed members of our Clinical Advisory Board play a critical role in providing clinical, regulatory and marketing advice to Ondine in support of the commercialization of Periowave™,” said Carolyn Cross, President and CEO of Ondine Biopharma. “Ondine wishes to congratulate Dr. Darveau for being recognized by his peers for his outstanding contributions to research in the periodontal field.”

“I am delighted to be a part of this distinguished board of internationally recognized experts,” stated Dr. Lawrence Meskin, Chairman of the Clinical Advisory Board. “Ondine’s Periowave™ Photodisinfection system is a remarkable new technology that promises to revolutionize the way we treat periodontal diseases.”

Members of the Clinical Advisory Board:

- *Dr. Lawrence Meskin* (Chairman) D.D.S. M.S.D. M.P.H. Ph.D. is a Professor, and Director of Continuing Education at the University of Colorado, School of Dentistry, and past Dean of the University of Colorado’s School of Dentistry, and former Editor of the Journal of the American Dental Association. He currently is Chairman of the Editorial Board of Dental Abstracts and is a reviewer and board member for a number of medical and dental journals.
- *Dr. Steve Bruce* D.D.S. is a private general dental practitioner and the ADA’s 11th District Trustee, which includes Washington, Oregon and Alaska.
- *Dr. Greg Chadwick*, D.D.S. is an endodontist and currently serves as the Dean and Associate Vice Chancellor for Oral Health at East Carolina University in Greenville, North Carolina. He is also past president of the American Dental Association, president of numerous dental organizations and is a past-president of the Dental Foundation of North Carolina.

- *Dr. Sharon Compton* Ph.D. R.D.H. is an Associate Professor and Director of the Dental Hygiene Program at the University of Alberta, Edmonton.
- *Dr. Richard Darveau* Ph.D. is a Professor in the Departments of Periodontics and Oral Biology, at the University of Washington School of Dentistry, Seattle. He was recently named Honorary Professor at the University of Hong Kong. Dr. Darveau is on the editorial boards of the Journal of Antibiotics and the Journal of Periodontal Research.
- *Dr. Robert Genco* D.D.S. Ph.D., is a Distinguished Professor in the Department of Oral Biology, School of Dental Medicine, and in the Department of Microbiology, School of Medicine and Biomedical Sciences, at the State University of New York at Buffalo. Dr. Genco is most recognized for his studies assessing risk factors for periodontal disease among behavioral, environmental and genetic factors. He is also well known for his pioneering work linking periodontal infections as risk factors for diabetes and cardiovascular disease.
- *Dr. Gareth Griffiths* D.D.S. Ph.D. is a Professor of Periodontology, Adult Dental Care Department at The School of Clinical Dentistry, University of Sheffield, England.
- *Ms. Trisha O'Hehir* R.D.H is a Past-President of the Arizona State Dental Hygienists' Association and an international speaker, author, instrument designer and currently the editorial director for Hygienetown Magazine.
- *Dr. Tim Rose* D.D.S. is a past President of both the American Academy of Periodontology and the American Dental Association and a practising periodontist in Appleton, Wisconsin.

About Periowave™ and Photodisinfection (PDD)

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodisinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business PLC, University College London. Additional information about Periowave™ is available at www.periowave.com.

About Ondine Biopharma Corporation:

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a

number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

For further information please contact:

Carolyn Cross
President and Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555
ccross@ondinebiopharma.com

Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269
cbessant@equicomgroup.com